Published in Nature on November 20, 2013
PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov (2014) 4.81
Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov (2014) 2.77
A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling. Cell (2016) 2.26
CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. PLoS One (2016) 2.08
Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Chem Biol (2014) 1.95
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science (2016) 1.73
Serine Metabolism Supports the Methionine Cycle and DNA/RNA Methylation through De Novo ATP Synthesis in Cancer Cells. Mol Cell (2016) 1.71
Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer (2014) 1.71
A combinatorial strategy for treating KRAS-mutant lung cancer. Nature (2016) 1.69
ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med (2014) 1.66
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov (2015) 1.64
Rational design of small molecule inhibitors targeting the Ras GEF, SOS1. Chem Biol (2014) 1.45
Beyond BRAF: where next for melanoma therapy? Br J Cancer (2014) 1.26
Molecular pathways and therapeutic targets in lung cancer. Oncotarget (2014) 1.16
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2016) 1.13
A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer. Clin Cancer Res (2014) 1.11
KRAS as a Therapeutic Target. Clin Cancer Res (2015) 1.11
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize? Clin Cancer Res (2015) 1.08
Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway. Proc Natl Acad Sci U S A (2015) 1.08
Adaptive stress signaling in targeted cancer therapy resistance. Oncogene (2015) 1.07
Comprehensive assessment of cancer missense mutation clustering in protein structures. Proc Natl Acad Sci U S A (2015) 1.06
Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood (2014) 1.05
Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange. Proc Natl Acad Sci U S A (2014) 1.04
Proteome-wide covalent ligand discovery in native biological systems. Nature (2016) 1.04
In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C. Proc Natl Acad Sci U S A (2014) 1.02
Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res (2016) 0.99
Protein domain-level landscape of cancer-type-specific somatic mutations. PLoS Comput Biol (2015) 0.97
Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices. Proc Natl Acad Sci U S A (2015) 0.97
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol (2015) 0.97
Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia (2014) 0.97
Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma. Onco Targets Ther (2014) 0.96
Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models. Mol Cancer Ther (2015) 0.95
A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin. Sci Transl Med (2014) 0.95
Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. Genes Dis (2015) 0.94
On human disease-causing amino acid variants: statistical study of sequence and structural patterns. Hum Mutat (2015) 0.93
Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel) (2015) 0.93
Site-specific processing of Ras and Rap1 Switch I by a MARTX toxin effector domain. Nat Commun (2015) 0.93
Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting. Front Oncol (2014) 0.93
BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oncotarget (2014) 0.92
Twenty years on: the impact of fragments on drug discovery. Nat Rev Drug Discov (2016) 0.92
High-Affinity Interaction of the K-Ras4B Hypervariable Region with the Ras Active Site. Biophys J (2015) 0.92
The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol (2016) 0.92
Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines. Sci Rep (2015) 0.91
RAS isoforms and mutations in cancer at a glance. J Cell Sci (2016) 0.91
GTP Binding and Oncogenic Mutations May Attenuate Hypervariable Region (HVR)-Catalytic Domain Interactions in Small GTPase K-Ras4B, Exposing the Effector Binding Site. J Biol Chem (2015) 0.90
New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs. Clin Cancer Res (2014) 0.90
Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities. Front Physiol (2014) 0.88
Targeting oncogenic KRAS in non-small cell lung cancer cells by phenformin inhibits growth and angiogenesis. Am J Cancer Res (2015) 0.88
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat Rev Drug Discov (2016) 0.88
Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer. Eur J Nucl Med Mol Imaging (2014) 0.87
The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer. Acta Pharmacol Sin (2015) 0.87
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol (2016) 0.87
Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Cancer Res (2015) 0.86
Treatment Individualization in Colorectal Cancer. Curr Colorectal Cancer Rep (2015) 0.85
Cancer: The Ras renaissance. Nature (2015) 0.85
Structure-based inhibition of protein-protein interactions. Eur J Med Chem (2014) 0.85
Early and multiple origins of metastatic lineages within primary tumors. Proc Natl Acad Sci U S A (2016) 0.84
Drugging the addict: non-oncogene addiction as a target for cancer therapy. EMBO Rep (2016) 0.84
Discovery of a Direct Ras Inhibitor by Screening a Combinatorial Library of Cell-Permeable Bicyclic Peptides. ACS Comb Sci (2015) 0.84
Inhibition of Ras signaling by blocking Ras-effector interactions with cyclic peptides. Angew Chem Int Ed Engl (2015) 0.84
Detection of secondary binding sites in proteins using fragment screening. Proc Natl Acad Sci U S A (2015) 0.83
Activation of RAS family members confers resistance to ROS1 targeting drugs. Oncotarget (2015) 0.83
An improved isoprenylcysteine carboxylmethyltransferase inhibitor induces cancer cell death and attenuates tumor growth in vivo. Cancer Biol Ther (2014) 0.83
The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B. Sci Rep (2016) 0.83
The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations. Onco Targets Ther (2016) 0.83
An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation. Immunol Res (2014) 0.83
A high-throughput assay for small molecule destabilizers of the KRAS oncoprotein. PLoS One (2014) 0.82
Targeting RAS-mutant cancers: is ERK the key? Trends Cancer (2015) 0.82
Targeting molecular addictions in cancer. Br J Cancer (2014) 0.82
Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers. Cancer Sci (2014) 0.82
Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors. Mol Cancer Ther (2015) 0.82
Systematic Prioritization of Druggable Mutations in ∼5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach. Mol Cell Proteomics (2015) 0.82
Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK. Nat Commun (2016) 0.82
Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers. Oncotarget (2015) 0.82
Targeting pathways downstream of KRAS in lung adenocarcinoma. Pharmacogenomics (2014) 0.82
Binding hotspots on K-ras: consensus ligand binding sites and other reactive regions from probe-based molecular dynamics analysis. Proteins (2015) 0.82
Development of synthetic lethality anticancer therapeutics. J Med Chem (2014) 0.82
Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression. Oncotarget (2016) 0.81
Biophysics in drug discovery: impact, challenges and opportunities. Nat Rev Drug Discov (2016) 0.81
Direct Ras Inhibitors Identified from a Structurally Rigidified Bicyclic Peptide Library. Tetrahedron (2014) 0.81
Inhibition of Acid Sphingomyelinase Depletes Cellular Phosphatidylserine and Mislocalizes K-Ras from the Plasma Membrane. Mol Cell Biol (2015) 0.81
pMD-Membrane: A Method for Ligand Binding Site Identification in Membrane-Bound Proteins. PLoS Comput Biol (2015) 0.81
Drug discovery: Pocket of opportunity. Nature (2013) 0.81
Inhibition of RAS function through targeting an allosteric regulatory site. Nat Chem Biol (2016) 0.81
Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells. Oncotarget (2015) 0.80
Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view. Chem Soc Rev (2016) 0.80
Combined rational design and a high throughput screening platform for identifying chemical inhibitors of a Ras-activating enzyme. J Biol Chem (2015) 0.80
New option for the initial management of metastatic pancreatic cancer? J Clin Oncol (2014) 0.80
K-Ras protein as a drug target. J Mol Med (Berl) (2016) 0.80
Kirsten Ras* oncogene: significance of its discovery in human cancer research. Oncotarget (2016) 0.80
Oncogene withdrawal engages the immune system to induce sustained cancer regression. J Immunother Cancer (2014) 0.80
Disulfide-Trapping Identifies a New, Effective Chemical Probe for Activating the Nuclear Receptor Human LRH-1 (NR5A2). PLoS One (2016) 0.80
KRAS mutant lung cancer: progress thus far on an elusive therapeutic target. Clin Transl Med (2015) 0.80
Onco-Golgi: Is Fragmentation a Gate to Cancer Progression? Biochem Mol Biol J (2015) 0.80
KRAS Engages AGO2 to Enhance Cellular Transformation. Cell Rep (2016) 0.79
Systematic Targeting of Protein-Protein Interactions. Trends Pharmacol Sci (2016) 0.79
Molecular Biomarkers of Pancreatic Intraepithelial Neoplasia and Their Implications in Early Diagnosis and Therapeutic Intervention of Pancreatic Cancer. Int J Biol Sci (2016) 0.79
Overview of simulation studies on the enzymatic activity and conformational dynamics of the GTPase Ras. Mol Simul (2014) 0.79
Targeting GTPases in Parkinson's disease: comparison to the historic path of kinase drug discovery and perspectives. Front Mol Neurosci (2014) 0.79
The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet (2008) 16.09
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res (2006) 13.98
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med (2005) 13.40
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science (1987) 7.69
Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP. Mol Cell Biol (1988) 7.06
Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc Natl Acad Sci U S A (1984) 6.45
Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. Science (1990) 5.76
Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation. Nature (1989) 5.38
Brefeldin A acts to stabilize an abortive ARF-GDP-Sec7 domain protein complex: involvement of specific residues of the Sec7 domain. Mol Cell (1999) 3.35
Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A (2012) 3.21
K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med (1990) 3.16
In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. Proc Natl Acad Sci U S A (2013) 3.10
Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew Chem Int Ed Engl (2012) 3.09
Dominant inhibitory mutations in the Mg(2+)-binding site of RasH prevent its activation by GTP. Mol Cell Biol (1991) 2.76
Site-directed ligand discovery. Proc Natl Acad Sci U S A (2000) 2.58
Kinetics of interaction of nucleotides with nucleotide-free H-ras p21. Biochemistry (1990) 2.55
Kinetic and structural analysis of the Mg(2+)-binding site of the guanine nucleotide-binding protein p21H-ras. J Biol Chem (1993) 2.23
Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol Cancer Ther (2011) 1.74
Structure-based mutagenesis reveals distinct functions for Ras switch 1 and switch 2 in Sos-catalyzed guanine nucleotide exchange. J Biol Chem (2001) 1.71
Structural basis for the specific inhibition of heterotrimeric Gq protein by a small molecule. Proc Natl Acad Sci U S A (2010) 1.49
Turning a protein kinase on or off from a single allosteric site via disulfide trapping. Proc Natl Acad Sci U S A (2011) 1.33
Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex. Bioorg Med Chem (1997) 1.27
Crystallization and preliminary X-ray analysis of the human c-H-ras-oncogene product p21 complexed with GTP analogues. J Mol Biol (1989) 1.24
Guanosine triphosphatase stimulation of oncogenic Ras mutants. Proc Natl Acad Sci U S A (1999) 1.20
Mutagenesis of the H-ras p21 at glycine-60 residue disrupts GTP-induced conformational change. Biochemistry (1995) 1.11
A Ras by any other name. Mol Cell Biol (2001) 1.07
The differential effects of the Gly-60 to Ala mutation on the interaction of H-Ras p21 with different downstream targets. J Biol Chem (1996) 0.93
Simple one-pot synthesis of disulfide fragments for use in disulfide-exchange screening. ACS Comb Sci (2011) 0.90
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell (2006) 10.06
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol (2009) 9.63
IRE1 signaling affects cell fate during the unfolded protein response. Science (2007) 9.01
Targets of the cyclin-dependent kinase Cdk1. Nature (2003) 8.05
Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov (2004) 7.84
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature (2007) 6.56
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell (2006) 6.15
T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A (2008) 5.97
Repairing research integrity. Nature (2008) 5.91
The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature (2012) 5.61
Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science (2005) 5.53
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Inhibitor hijacking of Akt activation. Nat Chem Biol (2009) 4.91
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
The site-specific installation of methyl-lysine analogs into recombinant histones. Cell (2007) 4.22
Features of selective kinase inhibitors. Chem Biol (2005) 4.07
Rewiring of genetic networks in response to DNA damage. Science (2010) 4.03
Global sequencing of proteolytic cleavage sites in apoptosis by specific labeling of protein N termini. Cell (2008) 4.00
The unfolded protein response signals through high-order assembly of Ire1. Nature (2008) 3.87
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol (2008) 3.84
Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell (2010) 3.79
Targeting the cancer kinome through polypharmacology. Nat Rev Cancer (2010) 3.74
The Ipl1-Aurora protein kinase activates the spindle checkpoint by creating unattached kinetochores. Nat Cell Biol (2005) 3.61
Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal (2010) 3.35
A chemical-genetic strategy implicates myosin-1c in adaptation by hair cells. Cell (2002) 3.34
Chemical genetic analysis of the time course of signal transduction by JNK. Mol Cell (2006) 3.32
Shaping development of autophagy inhibitors with the structure of the lipid kinase Vps34. Science (2010) 3.20
Functional organization of the S. cerevisiae phosphorylation network. Cell (2009) 3.15
The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol (2010) 3.15
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res (2009) 3.14
Chemical genetic screen for AMPKα2 substrates uncovers a network of proteins involved in mitosis. Mol Cell (2011) 2.99
A chemical-genetic approach to studying neurotrophin signaling. Neuron (2005) 2.93
Arterial-venous segregation by selective cell sprouting: an alternative mode of blood vessel formation. Science (2009) 2.82
Control of landmark events in meiosis by the CDK Cdc28 and the meiosis-specific kinase Ime2. Genes Dev (2003) 2.79
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A (2009) 2.77
The F box protein Dsg1/Mdm30 is a transcriptional coactivator that stimulates Gal4 turnover and cotranscriptional mRNA processing. Cell (2005) 2.75
Chemical genetic analysis of Apg1 reveals a non-kinase role in the induction of autophagy. Mol Biol Cell (2003) 2.72
Evolution of phosphoregulation: comparison of phosphorylation patterns across yeast species. PLoS Biol (2009) 2.67
A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res (2007) 2.62
Covalent capture of kinase-specific phosphopeptides reveals Cdk1-cyclin B substrates. Proc Natl Acad Sci U S A (2008) 2.53
Discovery of an allosteric site in the caspases. Proc Natl Acad Sci U S A (2004) 2.51
A second-site suppressor strategy for chemical genetic analysis of diverse protein kinases. Nat Methods (2005) 2.47
Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol (2007) 2.43
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med (2010) 2.42
Sexually dimorphic neurons in the ventromedial hypothalamus govern mating in both sexes and aggression in males. Cell (2013) 2.41
A semisynthetic epitope for kinase substrates. Nat Methods (2007) 2.40
Tethering: fragment-based drug discovery. Annu Rev Biophys Biomol Struct (2004) 2.37
Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells. Proc Natl Acad Sci U S A (2007) 2.37
Phosphoproteomic analysis reveals interconnected system-wide responses to perturbations of kinases and phosphatases in yeast. Sci Signal (2010) 2.36
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature (2012) 2.33
Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell (2008) 2.32
JNK2 is a positive regulator of the cJun transcription factor. Mol Cell (2006) 2.32
Searching for new allosteric sites in enzymes. Curr Opin Struct Biol (2004) 2.31
Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat Chem Biol (2007) 2.31
EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell (2013) 2.28
Two cyclin-dependent kinases promote RNA polymerase II transcription and formation of the scaffold complex. Mol Cell Biol (2004) 2.26
Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in Toxoplasma. Nature (2010) 2.25
Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol Cell (2007) 2.22
An integrated platform of genomic assays reveals small-molecule bioactivities. Nat Chem Biol (2008) 2.21
PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res (2008) 2.20
Nuclear HuR accumulation through phosphorylation by Cdk1. Genes Dev (2008) 2.14
A common allosteric site and mechanism in caspases. Proc Natl Acad Sci U S A (2006) 2.12
An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol (2005) 2.11
To stabilize neutrophil polarity, PIP3 and Cdc42 augment RhoA activity at the back as well as signals at the front. J Cell Biol (2006) 2.10
Chemical genetics: where genetics and pharmacology meet. Cell (2007) 2.09
Arabidopsis MAP kinase 4 regulates salicylic acid- and jasmonic acid/ethylene-dependent responses via EDS1 and PAD4. Plant J (2006) 2.07
Mps1 directs the assembly of Cdc20 inhibitory complexes during interphase and mitosis to control M phase timing and spindle checkpoint signaling. J Cell Biol (2010) 2.07
A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature (2011) 2.07
Tuning the activation threshold of a kinase network by nested feedback loops. Science (2009) 2.03
A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat Med (2011) 1.97
A surface on the androgen receptor that allosterically regulates coactivator binding. Proc Natl Acad Sci U S A (2007) 1.97
A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J (2008) 1.96
Inducible protein knockout reveals temporal requirement of CaMKII reactivation for memory consolidation in the brain. Proc Natl Acad Sci U S A (2003) 1.93
The cyclin-dependent kinase (CDK) family member PNQALRE/CCRK supports cell proliferation but has no intrinsic CDK-activating kinase (CAK) activity. Cell Cycle (2006) 1.90
Hierarchical modularity and the evolution of genetic interactomes across species. Mol Cell (2012) 1.88
Activation of specific apoptotic caspases with an engineered small-molecule-activated protease. Cell (2010) 1.85
A neo-substrate that amplifies catalytic activity of parkinson's-disease-related kinase PINK1. Cell (2013) 1.84
Phosphorylation of the transcription elongation factor Spt5 by yeast Bur1 kinase stimulates recruitment of the PAF complex. Mol Cell Biol (2009) 1.82
The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Annu Rev Biochem (2011) 1.80
Caspase substrates and cellular remodeling. Annu Rev Biochem (2011) 1.79
Binding of small molecules to an adaptive protein-protein interface. Proc Natl Acad Sci U S A (2003) 1.78
Plk1 self-organization and priming phosphorylation of HsCYK-4 at the spindle midzone regulate the onset of division in human cells. PLoS Biol (2009) 1.78
Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem (2004) 1.77
Maintenance of hormone-sensitive phosphoinositide pools in the plasma membrane requires phosphatidylinositol 4-kinase IIIalpha. Mol Biol Cell (2007) 1.77
Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Nat Struct Mol Biol (2012) 1.74
The effect of H3K79 dimethylation and H4K20 trimethylation on nucleosome and chromatin structure. Nat Struct Mol Biol (2008) 1.73
Small-molecule activators of a proenzyme. Science (2009) 1.72
Cdk1-dependent phosphorylation of Cdc13 coordinates telomere elongation during cell-cycle progression. Cell (2009) 1.72
Chemical inhibition of the TFIIH-associated kinase Cdk7/Kin28 does not impair global mRNA synthesis. Proc Natl Acad Sci U S A (2007) 1.71
Cdc28-Clb5 (CDK-S) and Cdc7-Dbf4 (DDK) collaborate to initiate meiotic recombination in yeast. Genes Dev (2008) 1.68
Nature-inspired design of motif-specific antibody scaffolds. Nat Biotechnol (2013) 1.68
Suppression of p53-dependent senescence by the JNK signal transduction pathway. Proc Natl Acad Sci U S A (2007) 1.67
Bio-orthogonal affinity purification of direct kinase substrates. J Am Chem Soc (2005) 1.67
The protein kinase Kin4 inhibits exit from mitosis in response to spindle position defects. Mol Cell (2005) 1.67
TFIIH and P-TEFb coordinate transcription with capping enzyme recruitment at specific genes in fission yeast. Mol Cell (2009) 1.66